




Centre for Integrative Bioethics, J. J. Strossmayer University of Osijek
Academy of Arts and Culture, J. J. Strossmayer University of Osijek 
tnedic@aukos.hr
Marija Heffer (Croatia)
Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek 
mheffer@mefos.hr
GENETICALLY DESIGNED VICTORY? – GENETICS, 
SPORT AND LEGAL DETERMINATION
Abstract
Certain gene variants in the human genome (polymorphism of common 
genes or alleles) give a comparative advantage in performing physical activities. 
Some of them are directly related to the structure of skeletal muscles and the 
ratio of white and red fibres in them. It has long been known that marathoners 
have a different body constitution than sprinters and that the endurance of the 
former is based on lower body mass and a high percentage of red muscle fibres, 
and the explosive power of the latter on larger muscles and the percentage 
of white muscle fibres. The genetic makeup of muscle is not the sole source 
of athletes’ advantage - genes that control the stress response affect physical 
strength but also the mental ability to cope with the pressure. Moreover, in 
sports competitions, genetic variations that lead to disease and, ultimately, 
injury or even death may give some specific physical advantage. In the case of 
Marfan’s syndrome, persons with this gene variant have long limbs and elastic 
joints, which is preferred especially in ball sports, which makes them recognized 
by coaches. Unfortunately, playing sports increases their risk of dilatation and 
dissection of the aorta, as a result of its wall extensibility.
The human body has its physical limits that can be pushed by strenuous 
training. This stretching of the ‘physical boundaries’ must be paired with a suitable 
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regeneration time for the effect to be greater than the possible damage. Also, 
time for regeneration is often denied to the most successful competitors who 
enter from one round of the competition to the next - as is the case at the World 
Cup. In not a small number of cases, success is traded with speedy metabolic 
aging and deterioration of health due to injuries. Given the fact that the value of 
top athletes is measured by money and reputation, there is an understandable 
interest in new methods to make their careful selection and personalize their 
training and diet. Our current understanding of molecular genetics is at such a 
stage that its application is possible and a tempting option for top sports. The 
advent of CRISPER technology goes a step further and allows the design of as yet 
unseen human abilities. Although the genetic application is in its infancy, sport 
organizations have to take a stand on which tests and which interventions are 
bioethically justified in sport competition and which are absolutely unacceptable. 
The big question is – what is a legal regulation of the same issue? Is the law 
following (bio)ethically determined state? Generally speaking, it is important 
to investigate what are exact legal acts that are connected with genetics in the 
first place and then with the combination of genetics and sport. Also, the goal 
is to examine whether the relevant legal acts are forbidding any kind of altering 
of human genome, in general and in sport. Can it be said that the law is one of 
the major stopping-mediums and “dams” of the complete genetic research that 
tends to be transhuman? 
Keywords: sport competitions, genomic analyses, athletic genes, sport 
science, law, legal protection
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Introduction
Sport science (kinesiology) and sport medicine are branches of basic and 
clinical science that closely deal with the physical performance and impact of 
various sport activities on health. The traditional interest of these professions, 
ever since ancient times and the origins of modern medicine, was to improve 
physical endurance and health (Hill, 2019). The link between proper nutrition 
and sport performance, as well as the link between the type of sport and possible 
sport injuries, was recognized very early on. Also, the benefits of physical training 
for mental health (Paluska and Schwenk, 2000) and vice versa, the benefits of 
mental training for athletic performance, were well studied (Vealey, 2007). In 
breaking some world records, it was not only the fitness and mental stability of 
athletes that was crucial but also the attitude of the profession towards human 
boundaries. One of the best-described examples was the mile run world record 
by Roger Bannister who, on May 6, 1954, at the Iffley Road (UK) racetrack, ran 
under four minutes (3:59.4) (World Athletics, News, Bannister, first man to 
run a sub-four-minute mile, dies)1. Since the first precisely measured running 
tracks were built in the 1850s, the men’s record time dropped from 4:28 (Charles 
Westhall, 1885 in London; in: Schiffer, 2008) to 4:01.4 (Gunter Hägg, 1945 in 
Malmő; World Athletics, Athlete Profile - Gunter Hägg)2 over the course of a 
century. Four minutes was considered the physiological limit of the human body 
and the record held for nine years. Bannister himself was a medical doctor with a 
deep interest in human physiology, autonomic nervous control of cardiovascular 
function in particular (MacAuley, 2005). After competing in the 1952 Olympics 
in Helsinki, which he considered a personal failure (fourth place in the 1500 m 
final), he set himself a new goal - to run a mile under four minutes. Bannister 
was deeply convinced that the 4-minute limit was imaginary and used inventive 
400 m interval training combined with periodic total rest for the purpose of 
recovery (supervised by his couch - Franz Stampfl) to break it. His record was 
broken in just 46 days (John Landy, June 21st, 1954 in Turku) in support of the 
hypothesis that the 4-minute figure was a tempting mythical limit just because 
it was very close to the record at the time and because it was round. The current 
men’s mile record is 3:43.13, held by Hicham El Guerrouj since 1999. Given that 
it has not been broken in 21 years (World Athletics, All-time Top lists, One 
1 URL: https://www.worldathletics.org/news/iaaf-news/roger-bannister-obituary,  
Retrieved: 2020-07-30
2 URL: https://www.worldathletics.org/athletes/sweden/gunder-hagg-14862355,  
Retrieved: 2020-07-30
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MileMen),3 it is probably closer to the physiological limit of human endurance 
in this discipline.
The marathon is the next discipline that occupies the human quest for 
boundaries. This tests the endurance of a completely different type from the 
one required for short and middle distance races. Marathoners risk metabolic 
collapse (the same one that cost Pheidippides, the famous Marathon victory 
herald, his life) if they do not manage to develop the necessary metabolic 
flexibility through long and persistent training and allow themselves a long 
enough period of regeneration between two races. International Association 
of Athletics Federations (IAAF) standardized marathon distance in 1921 to 
42.195  km. However, the first listed record dates back to 1908 when Johnny 
Hayes took the place of a disqualified Italian runner Dorando Pietri who got 
help in front of the finish line (London, UK) (Marathon Guide, Men’s World 
Record Times - 1905 to 1911).4 The men’s record (2:55:18.4) back then was 
broken by more than 50 minutes in the next 110 years (2:01:39, Eliud Kipchoge, 
Berlin Marathon 2018). The circumstances surrounding this record were very 
similar to those of the Roger Bannister era – 2:00:00 is a round figure very close 
to a possible human physiological limit. The most likely record striker, Kenyan 
long-distance runner Eliud Kipchoge, adopted an intermittent style of training 
which originates from Roger Bannister. Also, he is one of the three front-faces 
of Breaking2. Nike campaign announced in November 2016 (Runner’s World, 
Nike’s Audacious Plan: Break the 2-Hour Marathon Barrier in 2017).5 While 
Bannister fought against mainstream myth using knowledge of physiology and 
psychology, Kipchoge added technology to this. Nike’s research team developed 
personalized shoes The Nike ZoomX Vaporfly 4% and studied the influence of 
resistance and humidity of air to enhance the prospect of breaking the 2-hour 
limit. The first attempt to attack the record took place on May 6, 2017, in Monza, 
Italy. With the help of six pacers in a triangle formation who watched the big clock 
display and followed a green laser light indicating proper speed, Eliud Kipchoge 
reached the time of 2:00:25 and broke the world record of that time. The attempt 
was successfully repeated on October 12, 2019, at Prater Park, Vienna when he 
broke the imaginary line and achieved 1:59:40. Neither result was recognized by 
3 URL: https://www.worldathletics.org/records/all-time-toplists/middle-long/one-mile/
outdoor/men/senior?regionType=world&page=1&bestResultsOnly=true&firstDay=1900-01-
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IAAF due to the fact that these competitions were not open. Rather, all runners 
were carefully selected and responded to the invitation. In the meantime, Nike 
developed the next generation of breaking record shoes - the Nike ZoomX 
Vaporfly Next% - the use of which is controversial in races of this type because 
they give an undoubted advantage to competitors. The recognized world record 
still stands at 2:01:39 (Eliud Kipchoge, Berlin Marathon 2018) (World Athletics, 
All-time Top lists, Marathon Men).6
The Breaking2.Nike initiative showed that victory can be designed and 
the design consists of choosing the right competitors, their personalized 
programmed diet, training regimen, developing positive habits that contribute 
to metabolic flexibility/mental stability and understanding the environmental 
factors that contribute to choosing the right time to start the competition. If we 
add the genotyping of the most successful long-distance runners to this as the 
basis for the selection of competitors in some subsequent competitions, success 
is almost guaranteed.
The first goal of this paper is to give a brief overview of a recently discovered 
tool for advancing victory - genomic tests. The authors will also discuss possible 
gene–oriented personalized interventions affecting athletic performance and 
the dangers and bioethical problems that lie in their application. The second goal 
of this paper is to examine the legal situation of the whole issue. This especially 
pertains to the relevant legal acts and the provision of the same acts that are 
regulating the whole issue of a combination of genetics and sport to give an 
answer to the question is altering a human genome for the purpose of sport a 
legally valid action and in what way?
Review of previous research
All organisms have a genome that interacts with the environment to produce 
a phenotype. Genes for the one and the same trait come in different variants 
(alleles) and give rise to genomic variability (reflected, for example, as skin 
colour). Environmental factors further affect the appearance and variability of 
a phenotype (tanning of the skin under the influence of the sun).  In the case 
of many physical characteristics (e.g. height or weight) the total population 
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When searching for some extreme traits (e.g. intelligence) scientists are usually 
interested in a small percentage of individuals who are at one end of the curve. 
The similar logic is applied in the genomic selection of elite athletes. We 
assume that their exceptional skill is the result of their genetic makeup and 
environmental factors (training, diet) and they are at the very end of the 
Gaussian curve. The curve can be drawn for any interesting characteristic, such 
as running speed, strength, flexibility, maximum oxygen uptake, etc. In Genome 
Wide Association Studies (GWAS), scientists tried to compare the genomes of 
elite athletes (selected on the base of their exceptional physical characteristic 
and sport success) with the general population and look for gene variants that 
are significantly more often found in athletes than in general population. The 
success in pinpointing candidate genes is greater if the term ‘elite athlete’ is 
better defined. The larger the population of these athletes, the larger the general 
population tested. How large these numbers need to be in order to be able to 
draw reliable conclusions based on them can be seen from the most successful 
GWAS made so far for the purpose of determining the genetic basis of chronic 
polygenic diseases such as cardiovascular disease and diabetes. Two large 
consortia of scientists, CARDIoGRAM (Schunkert, Erdmann and Samani, 
2019) and C4D (Peden et al., 2011), have joined forces to find risky gene variants 
(polymorphisms) involved in the development of cardiovascular disease. Their 
joint CARDIоGRAMplusC4D study (Nikpay et al., 2015) identified 56 at-risk 
gene loci, and analysed more than 180,000 participants, about half of whom had 
cardiovascular disease. GWAS done for the purpose of identifying diabetes risk 
included 62,892 diabetics and 596,424 healthy controls, and 143 risk loci were 
identified (Xue et al., 2018). For comparison, one of the most recent GWAS 
studies of endurance athletes included 1520 samples of athletes and 2760 
samples of the general population (Rankinen et al., 2016). A metabolic study 
designed to identify genetically-influenced metabolites associated with athletic 
performance was performed on samples of 490 elite athletes who passed doping 
control at international competitions, and the study did not include samples 
of the general population (Al-Khelaifi et al., 2019). In addition to the problem 
that the studies of athletes were made on a small number of samples, the search 
for candidate genes is complicated by the fact that success in different sports 
depends on different phenotypic characteristics. For example, sprinters are 
more successful if fast-twitch fibres predominate in their muscle mass, while 
marathoners are the exact opposite – slow-twitch fibres should predominate in 
their muscle mass (Trappe et al., 2015). In addition, the classification of the elite 
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(successful) from the so-called non-elite (unsuccessful) athletes or the general 
population is complicated by the fact that, in spite of genetic make-up, proper 
training is crucial for sport success (Guth and Roth, 2013). It is, therefore, not 
surprising that none of the 249 identified genes that may represent an advantage 
for athletic performance are a good predictor of the success of the person who 
possesses it (Camporesi, 2013).
A good example of such a genetic trait is alpha-actin skeletal muscle isoform 
3 or F-actin cross-linking protein (ACTN3) whose polymorphism was linked 
back in 2003 to success in sports that prefer a sprint body type (Yang et al., 2003). 
The gene encodes a protein that participates in the assembly of the contractile 
apparatus of a muscle fibre. Two variants of this gene were investigated, of 
which the first, R577X, is present in almost 45% of the world’s population, and 
the second, 577XX, is found in 20% of the world’s population (Amorim et al., 
2015). People with the first variant express the protein in the fast-twitch muscles 
that make up a larger proportion of the sprinter’s muscle mass. Carriers of the 
second variant do not express the protein encoded by this gene at all. Namely, 
it is a mutation that does not cause disease, but significantly affects muscle 
development and is an example of very rare mutations in the loss of function 
in the human genome that give some advantage to their carriers (MacArthur et 
al., 2012). To make things more interesting, the first variant is associated with 
the success of sprinters, but the second variant is associated with the success of 
marathoners and scientists even consider that it gave a selective advantage in the 
movement of modern humans from Africa (Lee, et al., 2016). Nevertheless, both 
variants account for only 2% of total muscle performance while the remaining 
98% are attributed to environmental impact (Eynon et al., 2011). This is why the 
genotyping of this gene locus has little predictive value (web source: Mcarthur 
D. (2008) The ACTN3 sports gene test: What can it really tell you? Genetic 
Future).7
Another example is the ACE gene encoding angiotensin-1 converting enzyme. 
This enzyme is possessed by a number of cells, but its role in vascular endothelial 
cells and participation in the renin-angiotensin system, which is responsible 
for controlling blood pressure by regulating body fluid levels, is considered 
particularly important. Two variants of this gene have been described. The first 
has an insertion of 287 base pairs associated with less enzyme activity (so-called 
variant I). In the second case, this sequence is missing (delated or D variant) 
7 URL: http://scienceblogs.com/geneticfuture/2008/11/30/the-actn3-sportsgene-test-wha/ 
Retrieved: 2020-07-30.
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and the enzyme is less active (Rigat et al., 1990). The claim that people with the 
ACE I / I genotype have an advantage in sports that require great endurance 
while people with the D / D genotype are better in sports that require strength 
has prompted a number of conflicting opinions (Ma et al., 2013).  If we take 
into account the fact that 90 out of 100 elite marathoners of all time are of 
Kenyan or Ethiopian descent, who hold six consecutive world records in this 
discipline (International Association of Athletics Federations, 2018), there is no 
significant difference in the frequency of ACE I / D alleles between them and 
their respective general population (Scott et al., 2005). Therefore, it is obvious 
that a larger number of genes are responsible for their athletic success. Ahmetov 
and co-workers hypothesized that there were at least 93 genes (Ahmetov et al., 
2009) but none of them were specific to the marathon alone (Moir et al., 2019). 
In addition to select future elite athletes, genetics tests are also used as a tool 
of sports nutrigenomics to personalize nutrition in athletic populations. Since 
World War II (Ministry of Food (1951) The Urban Working-Class Household 
Diet 1940 to 1949. First Report of the National Survey Committee. His Majesty’s 
Stationery Office, London),8 it has been common to issue ‘one-size-fits-all’ dietary 
recommendations and food rationing to ensure a nutritional minimum that 
ensures the health of the population and fair distribution of available food. This 
is still applicable today in emergencies in its advance form (web source: UNHCR, 
UNICEF, WFP, WHO. Food and Nutrition Needs in Emergencies).9 Recently, 
dietitians got a more complete understanding of individual genetic differences 
regarding absorption, uptake, metabolic conversion, nutrient utilization, and 
excretion that are within physiological limits or belong to pathological variants. 
Lactose intolerance, caused by a relatively common genetic variant, has no 
severe consequences and is easily controlled (Storhaug, Fosse and Fadnes, 2017). 
Dietary fructose intolerance and phenylketonuria, which are less common, have 
more severe consequences and require a special diet (Macleod and Ney, 2010). 
However, if the patient adheres to them, health consequences are preventable 
(Jurecki et al., 2017). Examples of genetic variants which result in the inability 
to exploit an energy resource have led to the realization that ‘one-size-fits-all’ 
recommendations do not suit everyone and can seriously impair the quality of 
life of those who bear them. So-called personalized diets today are mostly used 
in the treatment of various diseases (e.g. metabolic and cardiovascular), but also 
in achieving optimal athlete performance (van Ommen et al., 2017).
8 Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/
attachment_data/file/549165/The_Urban_Working_-_Class_Household_Diet_1940-1949.pdf.
9 URL: https://www.unhcr.org/45fa745b2.pdf.
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A joint position statement from the American Dietetic Association, Dietitians 
of Canada, and the American College of Sports sets out views on the impact 
of diet on athletic performance and recovery from exercise (American College 
of Sports Medicine, American Dietetic Association and Dietitians of Canada, 
2000). The release lists evidence-based analyses regarding the satisfaction 
of energy requirements, the use of macronutrients and micronutrients, and 
optimal hydration. It is especially emphasized that physical activity increases 
the need for micronutrients that participate in energy production, regenerate 
muscle tissue, blood cell production, reduce the effects of oxidative stress, 
maintain the immune system, etc. Gene variants that reduce the ability to 
replenish micronutrients can significantly reduce athletic performance (Guest 
et al., 2019). Nutrigenomics allows the design of a precise personalized diet that 
corrects such deficiencies, not only to improve performance but also to preserve 
health or maintain reproductive fitness, especially in the case of women.
Dietary recommendations for athletes usually also include daily doses 
of supplements. As much as it is harmful to the health of athletes to omit 
supplements, it is even more dangerous to use them in excess. A good example is 
an iron replacement in athletes who have unfavorable variants of the TMPRSS6 
(increased risk for low levels of transferrin and hemoglobin saturation), TFR2 
(increased risk for decreased red blood count), and TF (increased risk for low 
ferritin) genes regulating hormone hepcidin expression which is crucial for 
the absorption of iron from the digestive tract. Due to the deficiency of iron 
absorption, these athletes have an increased risk of developing anemia (Guest et 
al., 2019), a condition that requires 3-6 months for reversal. In contrast, athletes 
with a pathological variant of the HFE gene are at risk for the chronic disease 
hemochromatosis due to iron overload. Although people with this disease have 
a genetic advantage in various sport disciplines (Semenova et al., 2020), iron 
replacement in their case pushes them even more into a pro-oxidative state 
and exacerbates the underlying disease (Zoller, 2004). Knowledge of individual 
genetic variability, along with biochemical tests to check the actual condition, 
allows for optimization and has the greatest effect on athletic success.
Today, dietitians have a whole list of genes that are interesting in terms of 
giving accurate dietary recommendations (genes that affect liver metabolism, 
absorption of vitamins and micronutrients, or even body composition). It has 
also been proven that disclosure of genetic information can motivate behavioral 
change and help introduce new habits (Nielsen, 2012). It should be noted that 
there are still a small number of studies that have investigated the interaction of 
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genes and diet in large enough cohorts of competitive athletes and controls that 
their results could be considered strong evidence. 
Discussion
From the point of view of sport medicine, genetic screening tests have 
the greatest justification if they are used for the purpose of predicting sport-
related injuries or performance-related conditions. Sudden cardiac death, 
usually of younger athletes, is not common, but it is devastating. It is a 
consequence of hereditary structural heart diseases or congenital electrical 
disorders (arrhythmias, canalopathies) associated with known genetic variants 
(Sarquella-Brugada et al., 2013). Such events cannot be completely avoided, but 
the superficiality of clinical examinations of young athletes is still surprising. 
Genetic tests that would predict such incidents have not yet been applied to 
athletes due to the rarity of these diseases but became a medical standard 
for preventing sudden death within affected family. In the last decades, there 
have been several sudden deaths on sport fields (Hank Gathers, Reggie Lewis, 
Haris Charalambous – Magic Harris) in athletes with Marfan syndrome - an 
autosomal dominant connective tissue disease associated with a mutation in the 
FBN1 gene (Loeys et al., 2010). These athletes more often engage in sports in 
which long limbs (basketball, volleyball, baseball) or elastic joints (skating) are 
an advantage. Diagnosis is a sufficient reason for their disqualification from the 
further competition (as it was the case with Isaiah Austin or Kayla Burt) for 
the association of this mutation with aortic dilatation and sudden cardiac death 
(Braverman et al., 2015).
Recently, there has been an increased interest in the genetics of sport injury 
prevention. Goodlin et al. (2015) reported single-base polymorphisms (SNPs) 
in various genes that increase the risk for low bone mineral density and stress 
fracture (67 SNPs), osteoarthritis (7 SNPs), anterior ligament tear (4 SNPs), 
and Achilles tendinopathy (6 SNPs). The same paper lists 39 SNPs associated 
with poorer athletic performance due to low circulating levels of iron, calcium, 
magnesium or vitamins E, D, B12, B6, B9, or risk levels of phytosterol and plasma 
homocysteine (Goodlin, et al., 2015). Genetic tests to identify these variants 
(polymorphisms) would be justified if done solely for the purpose of designing 
a personalized diet and injury prevention, but the possibility of their misuse to 
lower the price for a professional athlete or increase the amount of insurance for 
him or her cannot be ruled out.
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The flooding of the market with direct-to-consumer (DTC) genetic tests for 
sport performance aimed primarily at coaches and parents has prompted the 
reaction of a number of national sports organizations (Webborn et al., 2015; 
Vlahovich et al., 2017; Loland, 2015). These tests are mostly resented due to the 
lack of quality control and genetic counselling for the interpretation of genetic 
data to the consumer (Roth, 2012). However, even more objections should 
be made for the lack of evidence that either one of the tested genetic variants 
predicts an athlete’s performance better than the quality and length of training 
(Camporesi, 2013). Early talent directing and long-term training are known 
combinations for success, so it is not surprising that some parents feel the urge 
to provide their children with a head start using DTC genetic tests. On the other 
hand, reaching for such tests takes away the ethical and educational dimension 
of sport - it turns sport into a purpose in itself. In addition, children are deprived 
of the role of the subject in making their own choices. Even more frightening 
is the possibility of designing a baby. CRISPER technology opens the door to 
such possibilities. This new tool in molecular biology can be used to correct 
point mutations in both foetuses and adults, with some limitations related to 
target tissues. Correction of unfavourable traits is just one possible application 
which could be followed by upgrading and rearranging genetic material. All of 
the above could substantially change the way that we look at sport and society 
in general.
Legal view on the stated issue
Bioethical thought in a legal framework
The main mission of the law is to regulate all possibly predicted acts, 
behaviours, and events in modern society. The legal norm must be the pure 
reflection of society itself or to be precise about its general moral views, trends, 
and needs. Bioethical challenges provide a big assignment for law in general, 
which is to regulate all activities which arise from modern bio-research. Since the 
appearance of that kind of research, many different ethical issues arose. Now, the 
law has another complicated assignment – to deal with ethics. The relationship 
between the law and ethics/moral is one of the most crucial, but sometimes 
very controversial, parts of legal philosophy and jurisprudence. The legal aspect 
can give some sort of guidelines in solving ethical obstacles, but, very often, 
ethical and moral obstacles cannot be solved merely by the law (Nedić, 2020: 
257). The Latin and Roman law maxim stated, non omne quod licet honestum 
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est (not everything what is legal, is also honest/just/moral; see: Petrak, 2010: 95), 
dividing the law (in the way of legal positivists, as opposed to natural view of law) 
from all other entities: moral (ethics), justice, and freedom. However, due to all 
the differences between the terms, the fact is that the legal and ethical norms 
should be harmonised as best they can (Nedić, 2020: 257).
In that sense, there are two bioethical approaches of the researched problem. 
The first is the conception of genetic testing used for the purpose of improving 
health or preventing the occurrence of diseases and sport injuries. The second 
one is the usage of genetic tools for the purpose of creating the so-called designed 
baby and for the purpose of ‘improving’ the performance of adult athletes or, as 
we can say, a tendency to create some sort of superhuman in the field of sport. 
There is no doubt that, from an ethical and legal perspective, we can mark the 
first approach as purely justified, but can we do the same with the second one? 
If a genetic tool can cause severe damage to human health just in order to be 
successful in sport, can human society justify it, first in an ethical way and then 
in a legal one?  In the ethical way, there has already been genetic and (bio)ethical 
research done which has underlined the ethical question and debates of these 
kinds of ventures (e.g. Zajc Petranović et al., 2019). According to authors in the 
field of philosophy and bioethics of sport, when discussing the ethics of doping 
in general, but also in relation with human genetics, “four principles should be 
applied: harm principle (“are the procedures harmful to the athletes and are they 
disrupting and damaging the athlete’s health?), fairness principle (“gaining of 
an unfair advantage that needs to be assessed”), paternalistic principle (“should 
every athlete of age have the freedom to decide whether they want to change 
their genes?”), and coercion principle (“how can we be sure that the athletes 
have made their decisions autonomously and without coercion?)” (Škerbić, 
2016; Schneider, 2016). However, it is also very important to emphasize that 
there is indeed the possibility that correcting some of the genetic variants that 
necessarily lead to the disease could improve the health of the person who has 
the same variant, which can also affect that person’s physical ability. In this case, 
treatment has priority and the ‘side effect’ of treatment, which is seen as better 
athletic success, should not necessarily be interpreted as undesirable genetic 
engineering.
When it comes to the “property” of human body, Michel Aramini (2009: 266) 
underlines the principle of autonomy and principle of defence of physical life. 
Aramini sees the human body as unavailable human property, not the fact that 
the human body is indeed in any kind of disposition (principle of autonomy) 
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where, in a Kantian way, the human being is always a purpose and never any sort 
of medium (principle of defence of physical life) (Aramini, 2009: 254). What is 
the reflection of these kinds of thoughts in relevant legal regulations?
International law and the issue of human health
As we can see it here, one of the central issues of this kind of approach is 
related with the elaboration of human health. The big question is how does law 
(especially acts of international law) perceive the whole situation relating to 
health? 
The first concept is in an argument of legal protection of human life and 
human health. The right to health is a right that does not apply exclusively to 
the individual and his right to be “healthy” (individual right), but also the right 
that applies to the whole group of people (collective right), in a way to enable 
the collective a healthy life, healthy environment (environment), sustainable 
development, etc. Although there is no explicit term ‘right to health’ in 
international and European legal acts, the same term is itself inclusive, which 
means that it includes several important legal concepts. The right to health 
includes certain individual rights of the first (personal and political rights and 
freedoms) and second (economic, social, and cultural rights and freedoms) 
generation, but also collective rights of the third generation (such as the right 
to a healthy life and environment). According to Art. 25. of The Universal 
Declaration of Human Rights (United Nations, General Assembly resolution 
217 A, 1948) “everyone has the right to a standard of living adequate for the 
health and well-being of himself and of his family, including food, clothing, 
housing and medical care…”. Art. 12 of the International Covenant on Economic, 
Social and Cultural Rights (United Nations, General Assembly resolution 2200A 
(XXI), 1966) states that “the States Parties to the present Covenant recognize the 
right of everyone to the enjoyment of the highest attainable standard of physical 
and mental health.” It is the same with the regulation in the acts of the Council 
of Europe – the European Convention on Human Rights (Council of Europe, 
1950) and (Art. 11) of the European Social Charter (Council of Europe, ETS 
No.035, 1961). There is another important concept that the constitutions of all 
modern states provide (Art. 23 of the Croatian Constitution, Official Gazette 
56/90, 135/97, 08/98, 113/00, 124/00, 28/01, 41/01, 55/01, 76/10, 85/10, 05/14) 
– forbidden medical or scientific experimentation without consent. According 
to Art. 7 of the International Covenant on Civil and Political Rights (United 
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Nations, General Assembly resolution 2200A (XXI), 1966) “…no one shall be 
subjected without his free consent to medical or scientific experimentation”, 
which is a concept that emanates from Art. 5 of the Universal Declaration of 
Human Rights, Art. 3 of the European Convention on Human Rights.
If international legal acts are protecting the whole concept of human life 
and health, then the conclusion must be clear. The use of genetic tools for the 
purpose of creating the so-called designed baby, but also for the purpose of 
‘improving’ the performance of adult athletes, is a concept that violates the basic 
principles of human rights, more precisely the right to life and health standards 
of life. However, we are coming to an issue that the concept of human rights 
and human health cannot deal with. Genetic improvement of adult athletes is 
not something that is strictly violating the law in the aspect of right to health. 
As we saw, the only forbidden aspect are the medical and scientific pieces of 
research performed without consent. However, what if an athlete gives his 
written consent? In addition, there is a well-known legal and bioethical question 
of the status of the person for an unborn child and the fact that an unborn child 
is not the subject of law and has no legally determined rights. Meaning, if in 
some countries it is legal to “kill” an unborn child (abortion), is it really so bad to 
turn him into a superhuman? The legal concept of human health is only the first 
(of two) “sieves” of solving this kind of issue. 
Legal protection of genetic research
These two above mentioned aspects and questions of an adult athlete and 
unborn child are no longer related to human rights and health, but to legal 
protection of genetic research, which is the second “sieve” of solving this issue. 
The first problem, when it comes to law and genetic research, is the fact that 
there are not many concrete, unified, and universal legal acts which regulate this 
kind of issue. This leads us to the issue that many countries are legally solving and 
regulating genetic research in their own way. For example, although it is stated 
that “a large body of law exists in the member states of the European Union 
regarding the implementation of genomics technologies”, in its own Overview of 
EU National Legislation on Genomics (European Commission, JRC Science for 
Policy Report, 2018: 4-5), the European Commission (respectively JRC Science 
for Policy Report) underlines three report highlights:
“1. The existing national legislations seem to focus on genes, their variations 
and hereditability in living organisms, while scientific interests and 
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advancements, at the moment, have a more holistic view of the genomes of 
living organisms. Further reflections are needed to address this important 
gap in the legislative framework.
2.  There is a number of areas that are differentially addressed in the regulatory 
frameworks of the different member states, such as human somatic and 
germ line modifications (through the application of gene and genome 
editing technologies),
3.  Different legislative frameworks take into consideration the citizens’/
patients’ rights of having their personal genomic data characterised, used, 
and shared. An online interactive compendium should be produced and 
released, that would include all the legislative instruments retrieved and 
analysed for this report.” 
The same report also underlines that there is “the absence of an explicit EU 
legal framework on genomics (European Commission, JRC Science for Policy 
Report, 2018: 74)”. On the EU level, the GDPR10 and Regulation 536/2014 on 
clinical trials11 both regulate genetic research to a limited extent (Pormeister, 
2018: 709). Pormeister also emphasizes that “it must be noted that Regulation 
2017/746 on in vitro medical devices12 (applied as of May 26, 2022) will regulate 
genetic testing as well, however, only in a healthcare context and not regarding 
research.”
Comparatively, in Austria (The Gene Technology Act, BGBl. Nr. 510/1994, 
last amended BGBl. I Nr. 59/2018), Lithuania (The Law on Ethics in Biomedical 
Research of 2002), and the Netherlands (The Law on Medical Research on 
Humans of 26 February 1998) there are laws that are explicitly regulating the 
whole aspect of genetic research. In those places, it is forbidden to perform 
experiments on humans in a way that changes the germ line of humans (see: 
European Commission, JRC Science for Policy Report, 2018: 10). In other 
countries (The German Embryo Protection Act (1990) No 69/1990, The Maltese 
Embryo Protection Act (2013), The Portuguese Law no 12/2015 of 26 January on 
10 Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 
on the protection of natural persons with regard to the processing of personal data and on 
the free movement of such data, and repealing Directive 95/46/EC (General Data Protection 
Regulation), Official Journal of the European Union, L 119/1
11 Regulation 536/2014 on clinical trials on medicinal products for human use, and repealing 
Directive 2001/20/EC, Official Journal of the European Union, L 158/1
12 Regulation 2017/746 of the European Parliament and of the Council of April 5, 2017 on in 
vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 
2010/227/EU. [2017] Official Journal of the European Union L117/76.
Pannoniana, vol. IV, no. I (2020): 89-118
104
Personal Genetic Information and Health Information, The Slovenian Medicines 
Law (2014), The Swiss The Federal Act on Research Involving Embryonic Stem 
Cells (2003)), although there may not be any laws that explicitly regulate the 
issue of genetic research, alteration of the human germ line is also forbidden. 
The same fact also appears to be the case with the Croatian legislation where 
no specific and explicit genetic technology legislation could be found. The most 
relevant act of this issue is the Law on the Protection of Patients’ Rights (Official 
Gazette, No. 169/04, 37/08) where, according to Art. 22 of the same Law 
“interventions directed at changing the human genome can only be undertaken 
for preventative or therapeutic purposes and no interventions are allowed with 
the view to changing the patient’s germ line.”
However, while there is room for improvement regarding regulations of this 
kind of issue, in member states of EU and EU law in general there is an applicable 
legal act on the basis of the Council of Europe.13 According to the Convention on 
Human Rights and Biomedicine14 (Council of Europe, ETS No.164, 1997), in Art. 
12 it is stated that “tests which are predictive of genetic diseases or which serve 
either to identify the subject as a carrier of a gene responsible for a disease or to 
detect a genetic predisposition or susceptibility to a disease may be performed 
only for health purposes or for scientific research linked to health purposes, and 
subject to appropriate genetic counselling.” More relevant for the above stated 
issue, in the next article (13), the Convention is very clear: “An intervention 
seeking to modify the human genome may only be undertaken for preventive, 
diagnostic or therapeutic purposes and only if its aim is not to introduce any 
modification in the genome of any descendants.” It is important to emphasize 
that this Convention is an international treaty ratified by 29 European countries 
(not only EU members; Council of Europe, Chart of Signatures and Ratifications 
of Treaty 164),15 and which is, by the legal force, above the application of the 
law. According to the same Convention and interpretation of its mentioned 
provisions, genetically designing a “superhuman” is definitely not acceptable. 
13 “More specifically, the laws that would need to be evaluated concern: 
… 
4) Application of gene and genome editing technologies. Besides the above considerations on 
human applications of gene editing technologies, legislators should also address how to regulate 
the application of such technologies on animals and plants, especially on species relevant to the 
food and feed industry.”
14 Full name: Convention for the protection of Human Rights and Dignity of the Human Being 
with regard to the Application of Biology and Medicine (with its two Protocoles)
15 URL: https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/164/
signatures?p_auth=hY6c3JTC , Retrieved: 2020-08-4.
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On the basis of the United Nations, it is important to mention UNESCO’s 
Universal Declaration on the Human Genome and Human Rights (General 
Assembly resolution 53/152 of 9 December 1998), UNESCO’s International 
Declaration on Human Genetic Data (32 C/Resolution 15, 2003), as well as 
UNESCO’s Universal Declaration on Bioethics and Human Rights (32 C/Res. 
24, 2005) as one the of the most important international legal acts in the field 
of bioethics in general (see: Kirby, 2009). According to UNESCO’s International 
Declaration on Human Genetic Data: “human genetic data and human proteomic 
data may be collected, processed, used and stored only for the purposes of: 
(i) diagnosis and health care, including screening and predictive testing; (ii) 
medical and other scientific research, including epidemiological, especially 
population-based genetic studies, as well as anthropological or archaeological 
studies, collectively referred to hereinafter as “medical and scientific research”; 
(iii) forensic medicine and civil, criminal and other legal proceedings, taking into 
account the provisions of Article 1(c); (iv) or any other purpose consistent with 
the Universal Declaration on the Human Genome and Human Rights and the 
international law of human rights.” In that sense, an act that is directly related 
to the topic of the human genome is the Universal Declaration on the Human 
Genome and Human Rights where, in Art.1, it is stated that the human genome 
is “the heritage of humanity” determining the human being as it is. According 
to Art. 10, “no research or research applications concerning the human genome, 
in particular in the fields of biology, genetics and medicine, should prevail over 
respect for the human rights, fundamental freedoms and human dignity of 
individuals or, where applicable, of groups of people.” It is important to mention 
Art. 11 where it is stated that “practices which are contrary to human dignity, 
such as reproductive cloning of human beings, shall not be permitted” and 
also Art. 5 where it is stated that “research, treatment or diagnosis affecting an 
individual’s genome shall be undertaken only after rigorous and prior assessment 
of the potential risks and benefits pertaining thereto and in accordance with 
any other requirement of national law.” Although they are so-called soft law 
acts, these acts show a very important tendency of United Nations, as the most 
important and influential international organization and subject of international 
law, to legally regulate those kinds of ventures that are related to the human 
genome and genetics in general. According to the stated provisions, altering the 
human genome for the purposes of sport performance definitely could not be 
acceptable.  
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Designing a superhuman is definitely not acceptable according to another 
parameter. According to the Code of the World Anti-Doping Agency (Art. 
4.2.2. of World Anti-Doping Code, World Anti-Doping Agency, 2021) in the 
newest Prohibited List (Section M3 Gene and cell doping, World Anti-Doping 
Agency, 2020) it is stated that “the following, with the potential to enhance sport 
performance, are prohibited:
1.  The use of nucleic acids or nucleic acid analogues that may alter genome 
sequences and/or alter gene expression by any mechanism. This includes 
but is not limited to gene editing, gene silencing and gene transfer 
technologies.
2.  The use of normal or genetically modified cells.”
It is important to clarify that the World Anti-Doping Agency does not only 
prohibit substances, but also methods in which forbidden gene and cell doping 
are part of it. These kinds of methods, like all defined and listed methods in 
general, are prohibited at all times, not just in the time of competition or in 
particular sports (Prohibited List, World Anti-Doping Agency, 2020). This 
leads us to the conclusion that designing a “superhuman” in sport is not only 
unacceptable from an ethical perspective, but also from a legal one. It is not 
acceptable not only because it may harm human health, but also because of 
the fact that the same research is violating the pure essence of a human being, 
making him into something that is not provided by nature itself. Clearly, these 
two reasons, human health and preservation of the human genome, are two 
main reasons why the law is not justifying these kinds of ventures.
Conclusion
The distinctly competitive nature of sports and the orientation towards the 
market and the entertainment industry poses a temptation to athletes and their 
managers to increase the performance to the very limits by using all possible 
means. Athletes can achieve a high marketing price so investors use some 
traditional methods of their selection, but increasingly resort to unconventional 
ways of identifying potential talents (Breitbach, Tug and Simon, 2014). Few 
manage to pass the strict control of constitution, fitness, and self-discipline, 
and marketing mistakes come at a high price. In recent times, sport science and 
sport medicine had integrated knowledge from genetics (Trent and Yu, 2009) 
and nutrigenomics (Guest et al., 2019). Genetic tests have a few possible goals; 
to detect the so-called ‘performance enhancing polymorphism’ for the purpose 
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of early identification, programmed training, and dietary regime of potential 
athletic talents, rule out the existence of ‘life-threatening polymorphisms’ the 
negative consequences of which are triggered by physical exertion, creating 
personalized dietary instructions and a personalized training regimen. If they 
are used for the purpose of improving health or preventing the occurrence of 
diseases and injuries, the public opinion considers them to be ethically justified.
To date, more than 200 gene loci have been identified that could affect 
performance, but there is no valid evidence to justify their use in identifying 
future elite athletes for any of them. That is why early testing and forcing hard 
workouts is extremely ethically dubious. The use of genetic tools for the purpose 
of creating the so-called designed baby, but also for the purpose of ‘improving’ 
the performance of adult athletes, is dubious. Existing genetic tools still suffer 
from childhood diseases, but it is to be expected that they will develop rapidly, 
and the human race will find it difficult to resist the challenge of designing a 
superhuman. 
The elaborated ethical and especially legal unacceptability regarding this 
issue is, therefore, determined by two issues. The first is the parameter of legal 
protection of human health (first “sieve”), which of course this kind of research 
and venture may bring. The second one is the legal regulation of the whole issue 
of genetic modification (second “sieve”) which is not oriented primarily on the 
protection of human health. In that sense, the law must be oriented towards 
regulating and preventing not only genetic research that may be harmful for 
human health, but that kind of genetic research that is changing the whole 
nature and essence of the human being. Designing a “super-human” in sport and 
in general, apparently proved to be that kind of research. The law, apparently, 
really is an important stopping-medium and “dam” of complete genetic research 
that tends to be transhuman. Only three decades ago, sport organizations were 
obsessed with looking for potential fraud in the performance of men in women’s 
disciplines. According to the newest research papers, in the near future sport 
organizations could be prosecuting and chasing “super-humans” who compete 
in human disciplines.
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GENETIČKI DIZAJNIRANA POBJEDA? - GENETIKA, 
SPORT I PRAVNO ODREĐENJE
Sažetak
Određene genske varijante (aleli), daju komparativnu prednost kod obavljanja 
fizičkim aktivnostima. Neki od njih izravno su povezani sa gradom mišića 
odnosno omjerom bijelih i crvenih vlakana. Odavno je poznato da maratonci 
imaju drugačiju tjelesnu građu od sprintera te da se izdržljivost prvih temelji na 
nižoj tjelesnoj masi i visokom postotku crvenih mišićnih vlakana, a eksplozivna 
snaga potonjih na većim mišićima i postotku bijelih mišićnih vlakana. Genetička 
podloga sastava mišića nije jedini izvor prednosti nekog sportaša – primjerice 
geni koji kontroliraju stresni odgovor utječu na fizičku snagu, ali i na mentalnu 
sposobnost nošenja s pritiskom. Štoviše, u sportskim natjecanjima, varijacije 
gena koje dovode do bolesti, a u konačnici do ozljede ili čak smrti, mogu pružati 
određenu fizičku prednost. U slučaju Marfanovog sindroma, osobe s ovom 
varijacijom gena imaju dugačke udove i elastične zglobove, koji predstavljaju 
prednost osobito u sportovima s loptom, radi čega budu prepoznati od strane 
trenera. Na žalost, bavljenje sportom povećava im rizik od dilatacije i disekcije 
aorte kao posljedice rastezljivosti njene stijenke. 
Ljudsko tijelo ima svoje fizičke granice koje se napornim treninzima mogu 
pomaknuti. Ovo rastezanje ‘fizičkih granica’ mora biti upareno s prikladnim 
vremenom regeneracije da bi učinak bio veći od moguće štete. Također, vrijeme za 
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regeneraciju se često uskraćuje najuspješnijim natjecateljima koji ulaze iz jednog 
kruga natjecanja u drugi - kao što je slučaj na Svjetskom prvenstvu. U ne malom 
broju slučajeva, cijena uspjeha ubrzano je metaboličko starenje i pogoršanje 
zdravlja zbog ozljeda. S obzirom na činjenicu da se vrijednost vrhunskih sportaša 
mjeri novcem i ugledom, razumljiv je interes za nove metode njihovog pažljivog 
odabira, prilagođavanje treninga i prehrane. Naše trenutno razumijevanje 
molekularne genetike u takvoj je fazi da je njezina primjena moguća i primamljiva 
opcija u vrhunskim sportovima. Pojava CRISPER tehnologije ide korak dalje i 
omogućuje dizajn još neviđenih ljudskih sposobnosti. Iako je genetska primjena 
još u povojima, sportske organizacije moraju zauzeti stav o tome koji su testovi 
i koji zahvati bioetički opravdani u sportskom natjecanju, a koji su apsolutno 
neprihvatljivi. Veliko je pitanje i – kakva je pravna regulacija istog problema? 
Slijedi li pravo bioetički utvrđeno stanje? Općenito govoreći, važno je istražiti 
koji pravni akti su u prvom redu povezani s genetikom, a zatim s kombinacijom 
genetike i sporta. Također, cilj je ispitati da li relevantni pravni akti zabranjuju 
bilo kakvu promjenu ljudskog genoma, općenito a zatim u kontekstu sporta. 
Možemo li se reći da je zakon jedan od glavnih zaustavnih medija i “prepreka” 
cjelovitim genetskim istraživanjima koja teže transhumanizaciji?
Ključne riječi: sportska natjecanja, genomske analize, atletski geni, 
sportska znanost, pravo, pravna zaštita
